Ureaplasma urealyticum gyrB conferring resistance to fluoroquinolones

Accession ARO:3003305
CARD Short NameUure_gyrB_FLO
DefinitionPoint mutation in Ureaplasma urealyticum resulting in fluoroquinolone resistance.
AMR Gene Familyfluoroquinolone resistant gyrB
Drug Classfluoroquinolone antibiotic
Resistance Mechanismantibiotic target alteration
Classification11 ontology terms | Show
Parent Term(s)14 ontology terms | Show
+ confers_resistance_to_antibiotic enoxacin [Antibiotic]
+ confers_resistance_to_antibiotic ciprofloxacin [Antibiotic]
+ confers_resistance_to_antibiotic levofloxacin [Antibiotic]
+ confers_resistance_to_antibiotic moxifloxacin [Antibiotic]
+ confers_resistance_to_antibiotic gatifloxacin [Antibiotic]
+ confers_resistance_to_antibiotic lomefloxacin [Antibiotic]
+ confers_resistance_to_antibiotic nalidixic acid [Antibiotic]
+ confers_resistance_to_antibiotic norfloxacin [Antibiotic]
+ confers_resistance_to_antibiotic ofloxacin [Antibiotic]
+ confers_resistance_to_antibiotic trovafloxacin [Antibiotic]
+ confers_resistance_to_antibiotic grepafloxacin [Antibiotic]
+ confers_resistance_to_antibiotic sparfloxacin [Antibiotic]
+ confers_resistance_to_antibiotic pefloxacin [Antibiotic]
+ fluoroquinolone resistant gyrB [AMR Gene Family]
Publications

Kawai Y, et al. 2015. Antimicrob Agents Chemother 59(4): 2358-2364. In Vitro Activity of Five Quinolones and Analysis of the Quinolone Resistance-Determining Regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum Clinical Isolates from Perinatal Patients in Japan. (PMID 25645833)

Piccinelli G, et al. 2017. Infect. Genet. Evol. 47:64-67 Analysis of mutations in DNA gyrase and topoisomerase IV of Ureaplasma urealyticum and Ureaplasma parvum serovars resistant to fluoroquinolones. (PMID 27884651)

Resistomes

Prevalence of Ureaplasma urealyticum gyrB conferring resistance to fluoroquinolones among the sequenced genomes, plasmids, and whole-genome shotgun assemblies available at NCBI or IslandViewer for 413 important pathogens (see methodological details and complete list of analyzed pathogens). Values reflect percentage of genomes, plasmids, genome islands, or whole-genome shotgun assemblies that have at least one hit to the AMR detection model. Default view includes percentages calculated based on Perfect plus Strict RGI hits. Select the checkbox to view percentages based on only Perfect matches to AMR reference sequences curated in CARD (note: this excludes resistance via mutation as references in protein variant models are often wild-type, sensitive sequences).

Prevalence: protein variant model

SpeciesNCBI ChromosomeNCBI PlasmidNCBI WGSNCBI GI
No prevalence data


Detection Models

Model Type: protein variant model

Model Definition: Protein Variant Models (PVM) perform a similar search as Protein Homolog Models (PHM), i.e. detect protein sequences based on their similarity to a curated reference sequence, but secondarily screen query sequences for curated sets of mutations to differentiate them from antibiotic susceptible wild-type alleles. PVMs are designed to detect AMR acquired via mutation of house-keeping genes or antibiotic targets, e.g. a mutated gyrase resistant to aminocoumarin antibiotics. PVMs include a protein reference sequence (often from antibiotic susceptible wild-type alleles), a curated bit-score cut-off, and mapped resistance variants. Mapped resistance variants may include any or all of single point mutations, insertions, or deletions curated from the scientific literature. A Strict RGI match has a BLASTP bit-score above the curated BLASTP cutoff value and contains at least one curated mutation from amongst the mapped resistance variants, while a Loose RGI match has a bit-score less than the curated BLASTP bit-score cut-off but still contains at least one curated mutation from amongst the mapped resistance variants.

Bit-score Cut-off (blastP): 1200

Legend:

  • discovered in clinical, agricultural, or environmental isolates

  • discovered via laboratory selection experiments

  • ReSeqTB https://platform.reseqtb.org

Published Variants:


>gb|WP_004025678.1|+|Ureaplasma urealyticum gyrB conferring resistance to fluoroquinolones [Ureaplasma urealyticum]
MNDSNKENKYTAESIKVLEGLEAVRKRPGMYIGSTQSEGLHHMIWEIVDNSIDEAMGGFA
TVVKVIIKKDGVIRVEDDGRGIPVGIHEKTGLSGVETVLTVLHAGGKFDNDSYKVSGGLH
GVGASVVNALSKNFKVWVNKNYVQHYVEFINGGHAIEPLKIINDKDIKEKGTTIEFIPDF
EIMEENEWDELKIMARLKQLAYLNKGVNIEFESEMTNRKEKWHYEGGLKEYIADLNAEKE
PLFDAIVYGEEEKEVKVPGHNDQTYNIKCEVAFQYNNSYNNSTHSFCNNINTTEGGTHEE
GFKLAITRLLNKYAIDKKYLKDTDDKITKEDVSEGLTAIISIKHPNPQYEGQTKKKLGNS
EVRPYVNEITSIIFEKFLNENPEESKKIVAKVMQAAEARRRSHEAREATRRKSPFESNSL
PGKLADCSNRDSSVTEIYIVEGDSAGGSAKTGREREFQAILPLRGKIINVEKAKIDKIFA
NEEIQNMITAFGAGIGPEFNIEKLRYSKIIIMTDADVDGSHIRILLLTFFYRYMLPLIQN
GNVYIAQPPLYKVSYGKTIKYAYSDQELEKIKSTLLNTKYNIQRYKGLGEMNPDQLWETT
MDPKNRLLLKVNIEDAAIADKTFSLLMGDDVTPRKEFIEKNAKYVKNIDA



>gb|NC_011374.1|+|104284-106236|Ureaplasma urealyticum gyrB conferring resistance to fluoroquinolones [Ureaplasma urealyticum]
ATGAACGATTCTAATAAAGAAAATAAATACACCGCTGAAAGTATTAAAGTACTTGAAGGATTAGAAGCGGTACGAAAACGTCCTGGTATG
TATATTGGTTCAACTCAATCAGAAGGTTTGCACCATATGATTTGAGAAATTGTTGATAACTCAATCGATGAAGCAATGGGTGGTTTTGCA
ACAGTTGTTAAAGTTATTATAAAAAAAGATGGAGTAATACGAGTTGAAGATGATGGACGTGGAATTCCAGTTGGAATTCATGAAAAAACT
GGTTTATCAGGTGTTGAAACTGTATTAACTGTGTTGCATGCTGGAGGTAAATTTGATAATGATAGTTACAAAGTCTCTGGTGGATTACAT
GGTGTTGGTGCATCTGTTGTTAATGCTTTAAGTAAAAACTTTAAAGTTTGAGTTAATAAAAATTATGTTCAACATTACGTTGAATTTATT
AATGGTGGACATGCTATTGAACCATTAAAAATAATTAACGACAAAGATATCAAAGAAAAAGGAACAACAATTGAGTTTATTCCTGACTTT
GAAATCATGGAAGAAAATGAATGAGATGAGCTAAAAATAATGGCTCGTTTAAAACAATTAGCTTACCTTAATAAAGGTGTTAATATCGAA
TTTGAATCAGAAATGACTAATCGTAAAGAAAAATGACATTACGAAGGTGGTTTAAAAGAGTATATAGCTGATTTAAACGCTGAAAAAGAA
CCATTATTTGATGCTATTGTTTACGGTGAAGAAGAAAAAGAAGTTAAAGTTCCAGGTCACAATGATCAAACTTATAACATTAAATGTGAA
GTAGCATTTCAATACAATAATTCGTACAACAATTCAACACACTCATTCTGTAATAACATTAATACTACAGAAGGTGGAACACACGAAGAA
GGTTTTAAATTAGCGATTACACGTTTATTAAACAAATATGCAATCGATAAAAAGTATTTAAAAGACACTGATGATAAAATCACTAAAGAA
GACGTGAGCGAAGGGTTAACAGCGATTATTTCTATTAAGCACCCTAACCCTCAATATGAAGGTCAAACAAAGAAAAAATTAGGAAATAGT
GAAGTTCGTCCTTATGTTAATGAAATTACTTCTATAATTTTCGAAAAATTCTTAAATGAAAATCCAGAAGAATCAAAAAAAATTGTTGCT
AAAGTTATGCAAGCCGCTGAGGCACGTCGTCGTTCTCATGAAGCGCGTGAAGCTACAAGACGAAAATCACCATTTGAATCAAATTCATTA
CCAGGTAAATTAGCTGATTGTTCAAATCGTGATTCAAGTGTTACAGAAATTTATATTGTCGAAGGGGATTCAGCTGGTGGATCAGCAAAA
ACTGGTCGTGAACGTGAATTCCAAGCAATTTTACCATTGCGTGGAAAAATTATTAATGTTGAAAAAGCAAAAATTGACAAGATTTTCGCT
AATGAAGAAATTCAAAACATGATTACTGCTTTTGGAGCAGGAATAGGGCCTGAATTTAATATTGAAAAATTAAGATATTCAAAAATTATT
ATTATGACCGATGCCGATGTCGATGGTAGCCATATTCGAATCTTGTTATTAACATTCTTTTATCGATACATGTTACCATTGATTCAAAAT
GGTAATGTTTATATTGCTCAACCACCACTTTATAAAGTGAGTTATGGTAAAACAATTAAATATGCATATTCTGATCAAGAATTAGAAAAA
ATTAAATCAACATTGTTGAATACAAAATATAACATTCAACGTTATAAAGGGTTAGGGGAGATGAATCCTGATCAATTATGAGAAACAACA
ATGGATCCTAAAAATCGTCTTTTATTAAAAGTTAATATTGAAGATGCGGCAATCGCTGATAAAACATTTTCTTTATTAATGGGTGATGAT
GTAACACCACGAAAAGAATTTATTGAAAAAAATGCAAAATATGTAAAGAATATTGATGCTTAA